OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMSOne-year data reinforce that majority of infants potentially exposed to OCREVUS during pregnancy or breastfeeding exhibit antibody responsesFenebrutinib two-year Phase II data demonstrate near-complete suppression of disease activity at 96 weeks Basel, 24 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new ...